STAGE IV PROSTATE CANCER AJCC V8
Clinical trials for STAGE IV PROSTATE CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV PROSTATE CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV PROSTATE CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Prostate cancer breakthrough: pausing treatment may restore testosterone
Disease control OngoingThis study looks at whether men whose metastatic prostate cancer has responded very well to hormone therapy can safely take a break from treatment. The goal is to see if pausing therapy allows their testosterone levels to return to normal while keeping the cancer under control. A…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 01, 2026 15:43 UTC
-
New combo therapy targets hard-to-treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in 65 people with advanced prostate, bladder, or kidney cancer that has spread. The main goals are to find the safest dose and check side effects. Researchers hope this combination can he…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:43 UTC
-
New drug combo shows promise against Hard-to-Treat prostate cancer
Disease control OngoingThis study tests whether combining two drugs—golimumab (which reduces inflammation) and apalutamide (which blocks male hormones)—can shrink or slow advanced prostate cancer that no longer responds to standard hormone therapy. Eight men with metastatic castration-resistant prostat…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
Immunotherapy plus chemo shows promise for Tough-to-Treat cancers
Disease control OngoingThis early-stage trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. About 15 adults whose cancer has spread will receive the combination. T…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New drug combo aims to control spread of prostate cancer
Disease control OngoingThis study tests a three-drug combination (abiraterone, prednisone, and apalutamide) in 60 men with prostate cancer that has spread but hasn't yet been treated with hormone therapy. The goal is to see how long the treatment can control the cancer. Participants must have high-risk…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC